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ABSTRACT: Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment 
option. Based on limited evidence, it was performed in several dedicated stroke centers worldwide on selected patients. Since 
2015, EVT for patients with intracranial large vessel occlusion has quickly been implemented as standard treatment in many 
countries worldwide, supported by the revised international guidelines based on solid evidence from multiple clinical trials. We 
describe the development in use of EVT in the Netherlands before, during, and after the pivotal EVT trials. We used data from all 
patients who were treated with EVT in the Netherlands from January 2002 until December 2018. We undertook a time-series 
analysis to examine trends in the use of EVT using Poisson regression analysis. Incidence rate ratios per year with 95% CIs were 
obtained to demonstrate the impact and implementation after the publication of the EVT trial results. We made regional observation 
plots, adjusted for stroke incidence, to assess the availability and use of the treatment in the country. In the buildup to the MR 
CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT 
patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. Before the trial results were formally announced, a 
statistically significant increase in EVT-treated patients per year was observed (incidence rate ratio, 1.72 [95% CI, 1.46–2.04]), and 
after the trial publication, an immediate steep increase was seen, followed by a more gradual increase (incidence rate ratio, 2.14 
[95% CI, 1.77–2.59]). In 2018, the percentage of ischemic stroke patients receiving EVT increased to 5.8%. A well-developed 
infrastructure, a pragmatic approach toward the use of EVT in clinical practice, in combination with a strict adherence by the 
regulatory authorities to national evidence-based guidelines has led to successful implementation of EVT in the Netherlands. 
Ongoing efforts are directed at further increasing the proportion of stroke patients with EVT in all regions of the country.
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Endovascular treatment (EVT) in patients with acute ischemic stroke has been proven highly effective in randomized controlled trials.1–7 The MR CLEAN 
(Multicenter Clinical Trial of Endovascular Treatment of 
Acute Ischemic Stroke in the Netherlands) was the first 
to publish positive results in January 2015, immediately 
followed by several other trials.1
See related articles, p 1928, p 1932, p 1951,  
p 1961, p 1969 and p 1978
Before the start of the MR CLEAN trial in December 
2010, several studies had provided data suggesting that 
EVT might be beneficial, although convincing evidence 
was lacking.8,9 The Dutch stroke guidelines of 2008 men-
tioned EVT as a rescue treatment, preferably provided 
within the context of randomized trials. In the Nether-
lands, EVT for acute ischemic stroke was not reimbursed 
until 2013, when reimbursement to centers was made 
conditional on participation in the MR CLEAN trial. This 
reimbursement policy is still in place and reinforced by 
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guidelines and quality criteria provided by the profes-
sional societies and endorsed by regulating authorities.
In the early 2000s, 2 stroke centers started providing 
EVT as an experimental treatment in selected patients, 
inspired by the results of early trials and by local clini-
cal experience.10 After 2005, other centers gradually fol-
lowed. Still, before initiation of the MR CLEAN trial in 
2010, there were 2 centers in the Netherlands that had 
treated >50 patients with IAT. Currently, 17 comprehen-
sive stroke centers provide EVT in the Netherlands for a 
population of 17 182 000 inhabitants.
The European Stroke Organisation recently stated 
that in 2030, 95% of eligible patients across Europe 
should have access to reperfusion therapy and EVT 
rates should be over 5% in all European countries.11 
Although considerable efforts have been made, a 
recent study showed large differences between coun-
tries in terms of access to appropriate acute stroke 
treatment.12 Gaining understanding in the trends of EVT 
over time might not only provide insight into the acces-
sibility but also about the implementation of new treat-
ments in daily clinical practice.
In this article, we describe the trends in number of 
patients with acute ischemic stroke who were treated 
with EVT and the accessibility of EVT in the Netherlands 
in 3 time periods: before, during, and after the completion 
of the MR CLEAN trial.
METHODS
The data of the MR CLEAN TRIAL have been made publicly 
available at the Virtual International Stroke Trials Archive and 
can be accessed at http://www.virtualtrialsarchives.org/vista/. 
Individual patient data of the MR CLEAN pretrial registry and 
the MR CLEAN Registry cannot be made available under the 
Dutch law, as we did not obtain patient approval for sharing 
individual patient data, even in coded form. However, all syntax 
files and output of statistical analyses will be made available 
upon reasonable request.
Study Population
We analyzed data from the MR CLEAN pretrial period, the MR 
CLEAN trial, and MR CLEAN Registry.
In the pretrial period, we retrospectively and prospectively 
collected data of all patients with acute ischemic stroke who 
received EVT in the Netherlands from October 2002 until a 
center started participation in the MR CLEAN trial, which 
included its first patient in December 2010.13
Patient selection criteria and methods of the MR CLEAN 
trial have been reported previously.14 In short, the MR CLEAN 
trial was a clinical trial in which patients with a proximal intracra-
nial arterial occlusion in the anterior circulation were random-
ized to either EVT with usual care or usual care alone. Treatment 
should be started within 6 hours after onset of stroke symp-
toms. All patients or their legal representatives provided written 
informed consent before randomization in the MR CLEAN trial. 
The study protocol of the MR CLEAN trial was approved by a 
central medical ethics committee and the research board of 
each participating center.14
Directly after inclusion of the last patient in the trial by 
March 2014 and before the presentation of the MR CLEAN 
trial results at the World Stroke Conference in October 2014, all 
EVT-treated patients were enrolled in the MR CLEAN Registry, 
which is as a prospective, multicenter, observational study. For 
our current analysis, we used data from all patients registered 
until December 31, 2018.15 The MR CLEAN Registry was 
approved by the Medical Ethics Committee of the Erasmus MC, 
Rotterdam, the Netherlands (MEC-2014-235).
We assume that no patients were treated outside the 
MR CLEAN trial during the study period and that all patients 
treated before and after the trial are registered in either one of 
the registries.
Statistical Analysis
We analyzed differences between 3 time periods (pretrial 
period, MR CLEAN trial, and MR CLEAN Registry). Patients in 
the MR CLEAN trial who were randomized to usual care were 
also included, since EVT was considered in these patients.
We used Poisson regression or negative binomial regres-
sion to determine whether the incidence ratio of EVT changed 
during the pretrial period and MR CLEAN Registry with the 
denominator being the count of EVT in each year. We then 
computed incidence rate ratios with 95% CIs, using the first 
year of the time period as reference point. Data were checked 
for potential overdispersion (variance greater than the mean) 
to ensure that the assumptions of a Poisson distribution were 
met. All analyses were adjusted for the number of stroke 
patients per year.16–28
We calculated the use of EVT as a proportion of all patients 
in the Netherlands who were hospitalized with acute isch-
emic stroke (including cerebral hemorrhages) between 2002 
and 2018, which was based on reports of the Dutch Heart 
Association.22–26 Linear regression was used to estimate the 
number of ischemic stroke patients for years in which another 
definition of stroke was used or years in which only the number 
of patients hospitalized with acute stroke was reported.
Maps of the Netherlands at province level were cre-
ated using R package tmap.29 Geographic and demographic 
information was obtained from Statistics Netherlands and 
Kadaster.30,31 The number of EVT-treated patients by province 
was based on the location of first hospital admission. The den-
sity of EVT-treated patients was averaged by dividing the total 
number of patients by, respectively, the years of patient enroll-
ment and number of stroke patients per province. The latter 
was based on anonymized data obtained from central hospital 
registration systems.
All statistical analyses were performed in R statistical soft-
ware 3.4.2 (R Foundation for Statistical Computation, Vienna).
RESULTS
In this 16 years’ time period, 6394 patients were treated 
with EVT. In the pretrial period (2002–2010), 514 patients 
were treated with EVT. During the MR CLEAN trial 
(2010–2014), 500 patients were included of whom 233 
patients were randomized to intervention. In the ongoing 
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MR CLEAN Registry started directly after inclusion of the 
last patient in the MR CLEAN trial in March 2014, 5335 
patients were registered until December 2018.
Of all treated patients, 2299 (53%) patients were men; 
59% in the pretrial period, 58% in MR CLEAN trial, and 
52% in the MR CLEAN Registry. The median age was 
70 years (interquartile range [IQR], 58–79); 62 in pretrial 
patients (IQR, 51–71), 66 (IQR, 55–76) during the MR 
CLEAN trial, and 71 (IQR, 61–80) in the MR CLEAN 
Registry. The time from onset to groin puncture was 205 
minutes (IQR, 155–270). A median onset-to-groin-punc-
ture time of 237 minutes (IQR, 190–315) was observed 
in the pretrial population, which had increased to 260 
(IQR, 210–311) in the MR CLEAN trial and decreased 
to 195 (IQR, 150–260) in the MR CLEAN Registry. All 
baseline characteristics significantly differed between 
study periods (Table 1).
Trend Analyses
From 2006 onward, a gradual increase in thrombecto-
mies was observed (Figure 1). In the buildup to the MR 
CLEAN trial, more centers provided EVT, and a sharper 
increase was observed, which continued during the MR 
CLEAN trial. After the last inclusion in the MR CLEAN 
trial, the same level of increase was observed until the 
results of the EVT trials were presented in October 2014. 
After the presentation of the MR CLEAN trial results at 
the World Stroke Conference in October 2014, the num-
ber of patients treated with EVT increased steeply (Fig-
ure 1). During the pretrial period and following the steep 
increase that occurred immediately after the trial, in the 
MR CLEAN Registry period, a statistically significant 
gradual increase in EVT-treated patients per year was 
observed (pretrial: incidence rate ratio: 1.72 [95% CI, 
1.46–2.04], P<0.001; MR CLEAN Registry: incidence 
rate ratio: 2.14 [95% CI, 1.77–2.59], P<0.001).
Regional Differences
During the pretrial period, patients were predominantly 
treated in Utrecht—a province in the center of the 
Netherlands. During the trial phase, a similar pattern was 
observed, although the number of patients treated in 
other regions increased. After announcement of the trial 
results, the distribution of EVT-treated patients spread 
more evenly across the Netherlands (Figure 2).
Proportion of Acute Ischemic Stroke Patients 
Receiving EVT
In 2010, 23 771 patients were hospitalized with acute 
ischemic stroke in the Netherlands, of whom 170 (0.5%) 
received EVT. In 2014, 217 (0.8%) acute ischemic 
stroke patients received EVT. After the MR CLEAN trial, 
the percentage of acute ischemic stroke patients treated 
with EVT increased to 3.1% in 2015. In 2018, 29 244 
patients were admitted with acute ischemic stroke of 
whom 1712 (5.8%) received EVT (Figure 3; Table I in 
the Data Supplement).
DISCUSSION
We described the trends in use of EVT before, during, 
and after the MR CLEAN trial expressed as the coverage 
of EVT in the Netherlands across different regions and 
the proportion of stroke patients who received EVT.
Our time-trend analysis showed increasing rates of 
treated patients in 3 consecutive time periods. In the 
pretrial period, the number of treated patients before the 
MR CLEAN trial in the Netherlands was low. This was 
probably due to conservative recommendations in the 
national guidelines that recognized the low level of evi-
dence for this treatment and to the fact that EVT was not 
reimbursed in that time period. During the pretrial period, 
a strict policy regarding non–evidence-based treatments 
was maintained by insurance companies, government, 
and professional societies.
A strict national policy of evidence-based guidelines 
is meant to provide the best evidence-based care to the 
majority of patients. However, it has to be acknowledged 
that the pioneering centers, which provided EVT as an 
experimental treatment when guidelines were not yet 
Table 1. Baseline Characteristics
In Total: October  
2004 to June 2016  
(n=4308)
Pretrial: October 2004 
to December 2010 
(n=514)
MR CLEAN Trial: 
December 2010 to 
March 2014 (n=500)
MR CLEAN Registry: 
April 2014 to October 
2017 (n=3294) P Value
Age, y; median (IQR) 70 (58–79) 62 (51–71) 66 (55–76) 71 (61–80) <0.001
Men, n (%) 2299 (53) 305 (59) 292 (58) 1702 (52) <0.001
NIHSS, median (IQR) 16 (11–20) 16 (12–21) 16 (12–21) 16 (11–20) <0.001
SBP, mm Hg; mean (SD) 149 (28) 148 (24) 145 (25) 150 (28) 0.01
Intravenous alteplase treatment, n (%) 3217 (75) 323 (64) 445 (89) 2449 (75) <0.001
Onset-to-groin-puncture time, min; median (IQR) 205 (155–270) 237 (190–315) 260 (210–311) 195 (150–260) <0.001
mRS was missing in 373 patients; NIHSS was missing in 189 patients; SBP was missing in 189 patients. MR CLEAN Registry contains information on baseline 
characteristics up to October 2017. IQR indicates interquartile range; MR CLEAN, Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the 
Netherlands; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SBP, systolic blood pressure.
FO
CU
SE
D 
UP
DA
TE
S
Wiegers et al Endovascular Treatment in the Netherlands
1944  July 2020 Stroke. 2020;51:1941–1950. DOI: 10.1161/STROKEAHA.119.026731
accommodating this intervention, played an important 
role in the pretrial development of acute stroke networks 
and treatment experience necessary to successfully per-
form a randomized clinical trial.
The adherence to guideline-based treatment strate-
gies continued until the steep increase of EVT-treated 
patients just after the results of MR CLEAN were formally 
announced at the World Stroke Conference in October 
2014.32 From the last inclusion in the trial until the pre-
sentation of these results, the use of EVT increased with 
the same level as during the MR CLEAN trial. The sharp 
acceleration of EVT use after October 2014 indicates 
that centers and physicians quickly adopted EVT and 
rapidly reorganized their acute stroke care to be able to 
provide this new treatment to more patients, even ahead 
of incorporation of EVT in the national guidelines in 2017.
The Netherlands belong to the countries with one of 
the highest annual proportion of patients with ischemic 
stroke receiving EVT.12 In 2017, 5.1% of the acute isch-
emic stroke patients received EVT.12 In the United States 
Figure 1. Trends over time regarding the use of endovascular treatment (EVT) in patients with acute ischemic stroke, presenting 
the observed number of EVT procedures.
MR CLEAN indicates Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands.
Figure 2. Maps of the coverage of endovascular treatment (EVT) in the Netherlands per province in 3 different time periods 
(Pretrial, MR CLEAN trial [Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands], 
MR CLEAN Registry).
Number of EVT-treated patients for each province are indicated per province. The density of EVTs was averaged by dividing the total number of 
treated patients by the average incidence during the observation period in that province. The red dots indicate intervention centers.
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during the same time period, 3.3% of ischemic stroke 
patients were treated with EVT in selected centers.33
It has been estimated that about 10% of the patients 
with ischemic stroke are eligible for EVT.34,35 Therefore, it 
could be roughly estimated that almost 50% of the num-
ber of ischemic stroke patients eligible for EVT actually 
received this treatment in 2018. This implies that many 
patients who are eligible still do not receive the treat-
ment. This can be partially explained by the fact that a 
lot of patients arrived >6 hours after symptom onset, and 
treatment of patient in this late treatment window was 
not yet included in national and European guidelines.36,37 
Another explanation might be that not yet all patients 
who might benefit from EVT are being recognized in time 
prehospital and in hospital, even though CTA has been 
advised as standard diagnostic procedure for all patients 
with acute ischemic stroke.38 Also, in current clinical 
practice, most suspected stroke patients are first trans-
ported to the nearest hospital for immediate treatment 
with IVT, which can lead to delay of the start of EVT and 
worse outcomes because of additional time needed for 
transfer to an endovascular capable center.39
Acute stroke care in the Netherlands is organized 
as follows. A national network for acute medical care 
has been established, with expert committees for sub-
sections for acute stroke care, trauma, obstetrics, acute 
psychiatry, and acute myocardial infarction. The acute 
stroke care expert committee consists of vascular neu-
rologists representing all stroke centers in the region, 
a GP, ambulance service coordinators, and a secretary. 
Every region has a regional network protocol for acute 
stroke care, based on the national stroke guideline and 
the requirements proposed by the national societies 
of neurology and radiology. The regional protocol pre-
scribes the pathway from onset to ER of primary stroke 
center and intervention center. Triage systems are 
being evaluated for implementation in prehospital set-
tings, but meanwhile, all patients are being transferred 
to the most nearby hospital with IVT available40 (Figure 
I in the Data Supplement).
Our density plots show that some regions imple-
mented EVT earlier and with a faster rate than other 
regions. These between-region differences indicate that 
access to EVT in the Netherlands can still be improved. 
Increasing the availability of EVT might contribute to 
equally divided stroke care in the Netherlands, although 
the number of stroke units per ischemic stroke patients 
is already at a high level.12 Considering that patients 
treated with EVT at higher volume centers have better 
outcomes than those treated at lower volume centers 
and that time is brain, especially in EVT-eligible stroke 
patients,41–43 a careful trade-off between centralization 
and accessibility of acute stroke care should be made.43
Experience from related medical areas, for instance 
from cardiology, could provide valuable lessons and some 
guidance. In the eighties and nineties, patients with large 
myocardial infarction were being treated with thrombo-
lytics. But when the superiority of the more effective and 
Figure 3. Proportion of ischemic stroke patients receiving endovascular treatment in the Netherlands per year.
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safer percutaneous coronary intervention (PCI) had been 
established, the country-wide introduction of this therapy 
was hampered and delayed by almost a decade by the 
specific requirements that the hospitals offering this form 
of treatment had to meet. Not infrequent and serious com-
plications associated with the PCI procedure mandated 
the presence of on-site cardiac surgery in the early years 
following the introduction of PCI and limited the number 
of sites that could offer optimal treatment. Both technical 
and organizational developments subsequently made the 
requirements of on-site cardiac surgery less of an issue 
and gradually enabled the development of PCI programs 
in hospitals without on-site cardiac surgery from the year 
2002 onward. Since then, the number of sites offering pri-
mary PCI for large myocardial infarctions increased from 
16 to 30, more than sufficient to treat all patients with large 
myocardial infarctions within a reasonable time frame.44
Inspired by this example, professional societies, gov-
ernmental agencies, and insurance companies concluded 
that one stroke intervention center per million inhabitants 
should be sufficient. Hospitals are supported in providing 
EVT, given the relatively small effect on hospital costs but 
substantial cost savings in the social service sector.45,46 To 
facilitate the development of EVT centers in the Nether-
lands and to ensure sufficient quality, requirements have 
been kept at an essential minimum of 50 EVT procedures 
per center per year and include 24/7 availability, sufficient 
facilities, and trained personnel (Table 2). These require-
ments were proposed by the Dutch Society for Neurol-
ogy and the Dutch Society for Radiology and adopted by 
insurance companies and regulatory bodies. However, the 
requirements for EVT centers are being updated because 
of the extension of the time window for reperfusion treat-
ment based on advanced perfusion imaging.47–51 The 
national guidelines require acquisition of NCCT and CTA 
(or magnetic resonance imaging/MRA) in all patients with 
acute ischemic stroke and are being updated with perfu-
sion imaging for late-window ischemic stroke patients.
Table 2. Quality Criteria for Primary Stroke Centers Providing Intravenous Alteplase Treatment and for Stroke Intervention 
Centers Providing Endovascular Treatment for Ischemic Stroke, Established by the Professional Societies for Radiology and 
Neurology in 2017
Primary stroke centers should
 admit and treat at least 100 acute stroke patients annually (mean of last 3 y)
 have a median door-to-needle time of <45 min
 have CT and CTA, of cervical and intracranial vessels 24/7 available, with direct assessment provided by or supervised by a radiologist
 have treatment with intravenous alteplase 24/7 available, with the treatment performed by or under supervision of a neurologist, who has direct access to 
neuroimaging
 have a stroke team 24/7 available, with a stroke nurse under supervision of a neurologist
 have stroke unit with 24/7 care and 24/7 admission through ER
 have neurosurgery available 24/7 or collaboration with a nearby neurosurgical center
 have a registry of acute stroke patients, which includes the percentage of patients treated with intravenous alteplase and the number of patients admitted 
within 4.5 h after onset of stroke
 participate in a regional stroke service and have a regional coordinator
 have arrangements with an intervention center for endovascular treatment and with the regional ambulance service for rapid transfer of patients eligible for 
endovascular treatment
Stroke intervention centers should
 fulfill the criteria for primary stroke centers
 have a multidisciplinary team at least consisting of a neurologist, radiologist, interventionalist, and anesthesiologist
 provide EVT on a 24/7 basis with the multidisciplinary team
 have arrangements with at least one other center in the same region to provide EVT when because of unusual circumstances EVT is not available in their own 
center
 have at least 2 angio suites, of which one is readily available with sufficient and appropriate personnel
 be equipped with an intensive care unit and a stroke unit
 have a local protocol, which includes description of logistics, responsibilities of all involved professionals, patients’ safety, and benchmarks for door-to-needle 
and door-to-groin-puncture time
 have neurologists with vascular expertise available 24/7
 have at least 3 interventionalists
 perform at least 50 EVT procedures per year
 have at least 20 EVT procedures per interventionalist per year (procedures done by 2 interventionalists count for both)
 have median door-to-groin-puncture times of <60 min
 have a local registry of quality-of-care parameters concerning logistics, complications, and technical as well as clinical outcomes (at least door-to-groin-
puncture time and onset-to-groin-puncture time, eTICI, and mRS at 3 mo)
CT indicates computed tomography; CTA, computed tomography angiography; ER, emergency room; eTICI, expanded Thrombolysis in Cerebral Infarction;  EVT, 
endovascular treatment; and mRS, modified Rankin Scale.
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More than a decade ago, criteria were established by 
the national professional societies that require a 2-year 
training in neurointervention with certification that is open 
to all medical specialties but in practice to neurologists, 
radiologists, and neurosurgeons.52 Almost all interven-
tionists in the Netherlands are radiologists. For general 
interventional radiologists who want to qualify for EVT 
of ischemic stroke, a short additional training is required 
that amounts to doing at least 25 thrombectomies, 50 
digital subtraction angiographies, 200 other endovascu-
lar procedures, and assessment of 200 NCCT and ≥50 
head/neck CTA or MRAs under supervision.
Interestingly, during the trial, onset-to-groin times 
had increased by about 1 hour, and after the trial, a 
gradual decrease was noted. The increase may be 
attributed to the consent and randomization procedure 
in the trial, whereas improved awareness, logistics, and 
increasing experience has led to the gradual decrease 
after the trial. Median age of EVT treated patients 
increased, likely because trial results and guidelines 
point out that high age by itself should not be consid-
ered as a contraindication for EVT53 (Figure II through 
VI in the Data Supplement).
Our study has some limitations. No information about 
the residence of the EVT-treated patients was available 
for all time periods. Therefore, we estimated the cover-
age of EVT in the Netherlands based on the first hos-
pital admission. Since not all patients are at home at 
the moment of their stroke onset and the first hospital 
is often close to the place of stroke onset, this should 
reflect daily clinical care.
Our study only describes EVT in the Netherlands, and 
it does only touch upon factors that have facilitated its 
rapid implementation. Comparisons with other countries 
may help in this regard. Still, several factors may have 
played an important role in the implementation of EVT in 
the Netherlands, including the dense population (17 mil-
lion people living on an area of 33 671 km2, for an aver-
age population density of 510/km2), the dense highway 
network, the large number of primary stroke centers (85, 
5 per million inhabitants) and EVT centers (17, 1 per mil-
lion inhabitants),12 and last, an ambulance network that 
has to comply with the requirement that every patient 
should be picked up within 15 minutes after calling 112 
and should be delivered at the ER of the most nearby 
primary stroke center within 30 minutes.
CONCLUSIONS
A well-developed infrastructure, a pragmatic approach 
toward the use of EVT in clinical practice, in combina-
tion with a strict adherence by the regulatory authori-
ties to national evidence-based guidelines has led to 
successful implementation of EVT in the Netherlands. 
Ongoing efforts are directed at further increasing the 
proportion of stroke patients with EVT in all regions of 
the country.
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